Post-anaesthetic Shivering Amongst Patients Undergoing Cerebral Angiography

NCT ID: NCT03566628

Last Updated: 2019-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-01

Study Completion Date

2019-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates whether the use of warmed solutions during cerebral angiography reduces the incidence of post-anaesthetic shivering. Half of participants will receive pre-warmed (39ºC) isotonic saline, while the other half receives the same solution at room temperature.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Shivering is a physiologic reaction aimed at raising body temperature that is very common amongst patients undergoing cerebral angiographies. The use of pre-warmed solutions during the procedure may reduce the incidence of shivering amongst these patients. In this triple-blind randomised trial, a consecutive sample of participants receiving total intravenous anaesthesia (TIVA) and undergoing cerebral angiography will be allocated to receive a warmed (39ºC) solution of up to 500cc of isotonic saline or the same solution, but at room temperature. Patients requiring sedation, those expected to require mechanical ventilation after the procedure, those with diminished consciousness (Glasgow Coma Scale \<15 pts) and patients not wishing to participate will be excluded from the study. The primary endpoint for this study is the incidence of shivering up to 60 minutes after the procedure is completed. Shivering will be assessed using a validated scale by operators unaware of treament allocation. All analyses will be undertaken by a statistician that will not participate of the clinical assessment of included patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Angiography Shivering

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Warmed Saline

Patients allocated to this arm will receive a warmed (39ºC) solution of up to 500mL of isotonic saline. This solution will be administered directly to the cerebral vasculature as part of the angiography.

Group Type EXPERIMENTAL

Warmed Isotonic Saline

Intervention Type OTHER

Isotonic saline warmed to 39ºC.

Room-Temperature Saline

Patients allocated to this arm will receive isotonic saline at room temperature. This solution will be administered directly to the cerebral vasculature as part of the angiography.

Group Type ACTIVE_COMPARATOR

Room-Temperature Isotonic Saline

Intervention Type OTHER

Isotonic saline at room temperature

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Warmed Isotonic Saline

Isotonic saline warmed to 39ºC.

Intervention Type OTHER

Room-Temperature Isotonic Saline

Isotonic saline at room temperature

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients receiving TIVA
* Patients undergoing cerebral angiography

Exclusion Criteria

* Glasgow Coma Scale \<15 points prior to procedure
* Expected need of mechanical ventilation after procedure completion
* Use of sedatives
* Refusal to participate
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Carlos Van Buren

OTHER

Sponsor Role collaborator

Universidad de Valparaiso

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nathalie Lopez

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nathalie Lopez, MD

Role: STUDY_DIRECTOR

Hospital Carlos Van Buren

Alvaro Silva, MD

Role: PRINCIPAL_INVESTIGATOR

Universidad de Valparaiso

Felipe Martinez, M.D; M.Sc.

Role: PRINCIPAL_INVESTIGATOR

Universidad Andrés Bello

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Carlos Van Buren

Valparaíso, , Chile

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Chile

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nathalie Lopez, MD

Role: CONTACT

Felipe Martinez, M.D; M.Sc.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nathalie Lopez, M.D.

Role: primary

Alvaro Silva, M.D.

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UV-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Whole Body Cooling Using Phase Changing Material
NCT01138176 UNKNOWN PHASE1/PHASE2